Objectives: The classification of the vascular lesions is based on the clinical feature, natural history, and cellular characteristics of the lesions. Accuracy in the classification of the vascular lesions is therefore essential in order for clinicians to correctly diagnose and treat these lesions.

Conclusion: The presentation gives an update on the classification of the vascular lesions. Acquired vascular lesions such as telangiectasias, venous lakes, cherry angiomas and pyogenic granulomas are highlighted. Besides, vascular anomalies, including infantile hemangiomas, capillary, venous, lymphatic, and arteriovenous malformations, are described with emphasis on characteristics and differences.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: To assess the value of Tixel-assisted betablockers and sirolimus in the treatment of hemangiomas an port wine stains respectively.

Introduction: Infantile hemangiomas (IHs) are the most common vascular tumors in children. In the past few years, long term application of topical beta-blockers have been reported to be an effective treatment of superficial IHs. Port wine stains are usually treated with pulsed dye laser (PDL). Post PDL revascularization is one of the main causes of incomplete regression and recurrence. Recently, topical sirolimus have been shown to improve treatment outcome probably through minimizing post-laser revascularization.

Materials / method: This retrospective study of all cases of IHs PWS treated with Tixel enhanced transcutaneous delivery of beta-blocker and Rapamycin respectively, between 2018 and 2019 was performed. Epidemiologic, clinical, and treatment data, including effectiveness score and safety, were reviewed.

Results: Of the total number of 11 IHs, 7 (63.7%) showed a good response to treatment and 4 (36.3) had a partial response, thus all patients (100%) had good or partial response to treatment. No systemic or local adverse effects were reported. Three patients with PWS were treated. There were clinically significant differences in blanching responses favoring PWS receiving PDL + Tixel + Rapamycin as compared to PDL + Rapamycin alone. Transient hyperpigmentation was noted in 1 patient. Two patients developed mild transient irritation and dermatitis following the treatment on both halves.

Conclusion: For the IH patients, enhanced transcutaneous delivery of beta-blockers is a safe and efficient topical therapy for infantile hemangioma. For the PWS patients, the use of Tixel drug delivery system combined with topical rapamycin before and following PDL treatment can reduce the total number of required PDL sessions and increase clearance rates.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability